Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone.
-
Industry
-
Biotechnology Research
-
Company size
-
51-200 employees
-
Headquarters
-
Vancouver, Washington
-
Type
-
Public Company
-
Founded
-
2011
-
Specialties
-
generative AI, synthetic biology, biologics, drug discovery, antibody development, artificial intelligence, pharmaceuticals, and biotechnology